Medication info
Neo-Citalopram 100 mg (Sitagliptin Hydrochloride Hydrate)

Neo-Citalopram 100 mg (Sitagliptin Hydrochloride Hydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tablet
Manufacturer / importer
Green Cross Corporation
Appearance
A bright brown, round, biconvex film-coated tablet.
Packaging
28 tablets/box [(14 tablets/PTPX2)]
Approval status
Active

MFDS item code 202101814 · Approved 2021.02.24 · Insurance code 643606120

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken regardless of meals. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, section 5. General Precautions). Patients with renal impairment Because dose adjustment is required according to renal function, evaluation of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Ingredients

Manufacturer
Green Cross Corporation

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is used to enhance blood sugar control in patients with type 2 diabetes. It typically serves as an adjunct to diet and exercise regimens, and can be administered alone. If there is no prior experience with diabetes medication and blood sugar control is difficult with monotherapy, it can be used in combination with metformin. Additionally, it can be added to patients who do not achieve adequate blood sugar control with any of the following mono therapies: sulfonylureas, metformin, thiazolidinediones, or insulin. This medication aids in improving blood sugar regulation across various treatment combinations.

How to take

Adult dose

This medicine is administered at a dose of 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken regardless of meals. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, section 5. General Precautions). Patients with renal impairment Because dose adjustment is required according to renal function, evaluation of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered regardless of the timing of dialysis.

Precautions

This medication may cause severe allergic reactions after administration; therefore, if symptoms such as skin rash or difficulty breathing occur, use should be immediately stopped and a physician should be consulted. If symptoms of pancreatitis such as severe abdominal pain or vomiting appear during the use of this medication, medical personnel must be informed immediately. Patients with type 1 diabetes or diabetic ketoacidosis should not use this medication. Patients with allergies to this medication or its ingredients should avoid using it. Patients with impaired renal function should adjust the dosage of this medication and take it as directed by their doctor. When taking this medication, patients should be cautious of symptoms of hypoglycemia, especially when taking it in conjunction with insulin or sulfonylureas. If severe joint pain or skin blistering occurs, notify a doctor immediately, and discontinuation of the medication may be necessary. This medication is not recommended for pregnant or breastfeeding women, nor has its safety been established in children or adolescents under 18 years of age. Elderly patients should regularly monitor their renal function during treatment due to decreased kidney function. In cases of overdose, seek medical attention immediately for appropriate treatment; some can be removed by hemodialysis. While there are generally fewer interactions with other medications, caution is advised when taken with cyclosporine or digoxin. It is important to consult a doctor immediately if any unusual symptoms or discomfort occur while taking this medication.

Side effects

Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, nasopharyngitis, upper respiratory infection, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, severe and disability-associated arthralgia, blistering dermatitis resembling pemphigus, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute kidney failure, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased blood triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air exposure, ideally at room temperature between 1°C and 30°C. This storage helps maintain the medication's effectiveness and prevents degradation.

Appearance and packaging

Appearance

A bright brown, round, biconvex film-coated tablet.

Package unit

28 tablets/box [(14 tablets/PTPX2)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.